The Experts below are selected from a list of 468 Experts worldwide ranked by ideXlab platform
Yusuf Yilmaz - One of the best experts on this subject based on the ideXlab platform.
-
plasma Prohepcidin levels in patients with chronic viral hepatitis relationship with liver fibrosis
European Journal of Gastroenterology & Hepatology, 2010Co-Authors: Omer Fatih Olmez, Selim Gurel, Yusuf YilmazAbstract:OBJECTIVES Iron is deemed to play a crucial role in the pathophysiology of liver damage in patients with chronic viral hepatitis. Hepcidin has recently emerged as the key hormone in the regulation of iron balance and recycling. We assessed plasma Prohepcidin levels in patients with chronic viral hepatitis and investigated the association of this molecule with iron parameters, histologic activity index, and liver fibrosis scores. METHODS We enrolled 35 patients with chronic hepatitis C, 27 with chronic hepatitis B, and 21 healthy controls. Plasma levels of Prohepcidin were measured by enzyme-linked immunosorbent assay. RESULTS Mean Prohepcidin levels were significantly lower in patients with chronic hepatitis B than in those with chronic hepatitis C (P<0.001) and healthy comparison controls (P<0.05). In patients with chronic hepatitis C, Prohepcidin was independently associated with liver fibrosis scores (beta=-0.009, standard error=0.003, P<0.05). No association of Prohepcidin with iron parameters was found. CONCLUSION Significantly lower Prohepcidin levels are frequently found in patients with chronic hepatitis B. Levels of this molecule may represent a biochemical correlate of fibrosis in chronic hepatitis C virus infection.
-
Plasma Prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis
European journal of gastroenterology & hepatology, 2010Co-Authors: Omer Fatih Olmez, Selim Gurel, Yusuf YilmazAbstract:OBJECTIVES Iron is deemed to play a crucial role in the pathophysiology of liver damage in patients with chronic viral hepatitis. Hepcidin has recently emerged as the key hormone in the regulation of iron balance and recycling. We assessed plasma Prohepcidin levels in patients with chronic viral hepatitis and investigated the association of this molecule with iron parameters, histologic activity index, and liver fibrosis scores. METHODS We enrolled 35 patients with chronic hepatitis C, 27 with chronic hepatitis B, and 21 healthy controls. Plasma levels of Prohepcidin were measured by enzyme-linked immunosorbent assay. RESULTS Mean Prohepcidin levels were significantly lower in patients with chronic hepatitis B than in those with chronic hepatitis C (P
-
influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients
Medical Science Monitor, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P<0.01). CONCLUSIONS It is concluded that EPO therapy, besides enhancing erythropoiesis, modulates serum Prohepcidin levels in dialysis patients.
-
Influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients.
Medical science monitor : international medical journal of experimental and clinical research, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P
-
effect of fluvastatin on serum Prohepcidin levels in patients with end stage renal disease
Clinical Biochemistry, 2008Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Serdar Kahvecioglu, Ibrahim Akdag, Kamil DilekAbstract:Objectives Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol. Design and methods Because there is a paucity of data on the effect of statins on serum Prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n = 22) compared with placebo (n = 18) on circulating serum Prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia. Results Fluvastatin treatment decreased total cholesterol (P < 0.05), LDL-cholesterol (P < 0.01), hs-CRP (P < 0.05) and serum Prohepcidin levels (P < 0.05) significantly. Conclusion Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum Prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.
Mahmut Arabul - One of the best experts on this subject based on the ideXlab platform.
-
Relationship Between Prohepcidin and Cardiovascular Risk Markers in End Stage Renal Failure Patients
Turkish Nephrology Dialysis Transplantation, 2013Co-Authors: Mahmut Arabul, Mehmet Ali Eren, Emre Sarandol, Serdar Kahvecioglu, Yasemin Ustundag, Aysel Kaderli, Turker Emre, Ibrahim Dogan, Mustafa GulluluAbstract:OBJECTIVE: The leading cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease. Prohepcidin, which is the precursor of hepcidin is a peptide hormone produced by the liver, and appears to be the master regulator of iron homeostasis in humans. High Prohepcidin levels may contribute to progression of cardiovascular disease in end-stage renal insufficiency patients. However, any such association remains poorly understood. The purpose of the present study was to investigate the relationship between Prohepcidin and cardiovascular risk markers in end-stage renal failure patients.MATERIAL and METHODS: Twenty-two chronic hemodialysis patients, 21 chronic peritoneal dialysis patients, and 16 healthy controls were included in the present study. The levels of serum Prohepcidin (the precursor form of hepcidin), high sensitivity C-reactive protein (hs-CRP), troponin-T (TT), and cystatin C (CC) were determined using commercial kits. The left ventricular mass index (LVMI) was estimated using echocardiography.RESULTS: The levels of the CVD risk markers TT, CC, and Prohepcidin differed, with statistical significance, between the patient and control groups. Prohepcidin level was significantly associated with CC concentration (β=0.855, R2=0.73, p
-
relationship between Prohepcidin and cardiovascular risk markers in end stage renal failure patients son donem bobrek yetersizlikli hastalarda prohepsidin ve kardiyovaskuler risk belirtecleri arasindaki iliski
2013Co-Authors: Mahmut Arabul, Mehmet Ali Eren, Emre Sarandol, Mustafa GulluluAbstract:OBJECTIVE: The leading cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease. Prohepcidin, which is the precursor of hepcidin is a peptide hormone produced by the liver, and appears to be the master regulator of iron homeostasis in humans. High Prohepcidin levels may contribute to progression of cardiovascular disease in end-stage renal insuffi ciency patients. However, any such association remains poorly understood. The purpose of the present study was to investigate the relationship between Prohepcidin and cardiovascular risk markers in end-stage renal failure patients. MATERIAL and METHODS: Twenty-two chronic hemodialysis patients, 21 chronic peritoneal dialysis patients, and 16 healthy controls were included in the present study. The levels of serum Prohepcidin (the precursor form of hepcidin), high sensitivity C-reactive protein (hs-CRP), troponin-T (TT), and cystatin C (CC) were determined using commercial kits. The left ventricular mass index (LVMI) was estimated using echocardiography. RESULTS: The levels of the CVD risk markers TT, CC, and Prohepcidin differed, with statistical signifi cance, between the patient and control groups. Prohepcidin level was signifi cantly associated with CC concentration (β=0.855, R2=0.73, p<0.001), TT level (β=0.456, R2=0.20, p=0.002), and the LVMI (β=0.435, R2=0.19, p=0.003). However, no signifi cant association between Prohepcidin level and hs-CRP concentration was evident (β=0.124, R2=0.015, p<0.42). CONCLUSION: Our data suggest that the Prohepcidin level can serve as a biomarker of cardiovascular disease. This level is closely associated with the cardiovascular risk markers of CC and TT concentrations, as well as the LVMI.
-
influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients
Medical Science Monitor, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P<0.01). CONCLUSIONS It is concluded that EPO therapy, besides enhancing erythropoiesis, modulates serum Prohepcidin levels in dialysis patients.
-
Influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients.
Medical science monitor : international medical journal of experimental and clinical research, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P
-
effect of fluvastatin on serum Prohepcidin levels in patients with end stage renal disease
Clinical Biochemistry, 2008Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Serdar Kahvecioglu, Ibrahim Akdag, Kamil DilekAbstract:Objectives Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol. Design and methods Because there is a paucity of data on the effect of statins on serum Prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n = 22) compared with placebo (n = 18) on circulating serum Prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia. Results Fluvastatin treatment decreased total cholesterol (P < 0.05), LDL-cholesterol (P < 0.01), hs-CRP (P < 0.05) and serum Prohepcidin levels (P < 0.05) significantly. Conclusion Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum Prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.
Xi Huang - One of the best experts on this subject based on the ideXlab platform.
-
serum Prohepcidin is associated with soluble transferrin receptor 1 but not ferritin in healthy post menopausal women
Blood Cells Molecules and Diseases, 2008Co-Authors: Xi Huang, Eric T Fung, Christine Yip, Anne ZeleniuchjacquotteAbstract:Hepcidin is a 25-amino-acid iron peptide hormone originated from its two precursors of Prohepcidin (60-amino-acid) and preProhepcidin (84-amino-acid). Serum Prohepcidin levels have been widely used to evaluate iron overload in clinical and preclinical studies. However, its usefulness is often questioned and its stepwise conversion mechanism remains largely unknown. Using New York University Women’s Health Study subjects, we measured serum levels of Prohepcidin with ELISA and hepcidin with mass spectrometry as well as ferritin and soluble transferrin receptor 1 (sTfR1) in 45 normal healthy postmenopausal women over a 1-year period with 2 samples per subject. We found that serum Prohepcidin levels are correlated with the serum sTfR1 levels (r=0.45, p<0.01) but not to ferritin levels (r=0.08, p=0.60), suggesting that serum Prohepcidin is not a biomarker of iron overload that was originally thought and designed for. Interestingly, serum hepcidin levels are associated with serum ferritin levels (r=0.64, p<0.0001) but not with sTfR1 levels (r=0.04, p=0.69), indicating that hepcidin is a measure of iron overload. Although hepcidin is a downstream product of Prohepcidin, the amounts of hepcidin and Prohepcidin are not related to each other (r=−0.007, p=0.90) under normal physiological conditions. The interrelationships between sTfR1 and Prohepcidin or between ferritin and hepcidin suggest that ferritin- and sTfR1-sensed hepcidin conversion system exists in human body and maybe regulated at the post-translational level.
-
Serum Prohepcidin is associated with soluble transferrin receptor-1 but not ferritin in healthy post-menopausal women.
Blood cells molecules & diseases, 2008Co-Authors: Xi Huang, Eric T Fung, Christine Yip, Anne Zeleniuch-jacquotteAbstract:Hepcidin is a 25-amino-acid iron peptide hormone originated from its two precursors of Prohepcidin (60-amino-acid) and preProhepcidin (84-amino-acid). Serum Prohepcidin levels have been widely used to evaluate iron overload in clinical and preclinical studies. However, its usefulness is often questioned and its stepwise conversion mechanism remains largely unknown. Using New York University Women's Health Study subjects, we measured serum levels of Prohepcidin with ELISA and hepcidin with mass spectrometry as well as ferritin and soluble transferrin receptor 1 (sTfR1) in 45 normal healthy post-menopausal women over a 1-year period with 2 samples per subject. We found that serum Prohepcidin levels are correlated with the serum sTfR1 levels (r=0.45, p
Kamil Dilek - One of the best experts on this subject based on the ideXlab platform.
-
influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients
Medical Science Monitor, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P<0.01). CONCLUSIONS It is concluded that EPO therapy, besides enhancing erythropoiesis, modulates serum Prohepcidin levels in dialysis patients.
-
Influence of erythropoietin therapy on serum Prohepcidin levels in dialysis patients.
Medical science monitor : international medical journal of experimental and clinical research, 2009Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Bulent Baran, Cuma Bulent Gul, Guzin Kocamaz, Kamil DilekAbstract:BACKGROUND Anemia is a common finding in dialysis patients. Recent evidence has accrued that hepcidin, an iron regulatory peptide, may play a crucial role in the pathophysiology of this condition. This study investigated the effect of erythropoietin (EPO) therapy on serum levels of Prohepcidin, the pro-hormone of hepcidin, in patients with end-stage renal disease (ESRD) undergoing chronic dialysis treatment. MATERIAL/METHODS A total of 40 ESRD patients with renal anemia receiving either hemodialysis or peritoneal dialysis were included in this study. The patients were randomly allocated to EPO (subcutaneous 2000 microg three times weekly) plus parenteral iron (n=23) or parental iron only (n=17). Serum Prohepcidin levels were measured before and at the end of the study. RESULTS The two groups were comparable in their demographic and laboratory characteristics. No significant differences were found in hemoglobin, hematocrit, iron store indices, or serum levels of Prohepcidin at study entry. Significant increases in both hemoglobin and hematocrit as well as a decrease in serum Prohepcidin level were evident in the EPO group at the end of the 6-month follow-up in comparison with their values at study entry compared with the control group (P
-
effect of fluvastatin on serum Prohepcidin levels in patients with end stage renal disease
Clinical Biochemistry, 2008Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Serdar Kahvecioglu, Ibrahim Akdag, Kamil DilekAbstract:Objectives Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol. Design and methods Because there is a paucity of data on the effect of statins on serum Prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n = 22) compared with placebo (n = 18) on circulating serum Prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia. Results Fluvastatin treatment decreased total cholesterol (P < 0.05), LDL-cholesterol (P < 0.01), hs-CRP (P < 0.05) and serum Prohepcidin levels (P < 0.05) significantly. Conclusion Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum Prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.
-
Effect of fluvastatin on serum Prohepcidin levels in patients with end-stage renal disease.
Clinical biochemistry, 2008Co-Authors: Mahmut Arabul, Yusuf Yilmaz, Mehmet Ali Eren, Mustafa Gullulu, Serdar Kahvecioglu, Ibrahim Akdag, Kamil DilekAbstract:Anemia, low-grade inflammation and/or alterations in lipid metabolism are common findings in individuals with end-stage renal disease (ESRD) despite advances in dialysis treatment. Hepcidin, a key regulator of iron metabolism, may play an important role in the interdependence of inflammation and anemia in ESRD patients. Statins may reduce cardiovascular events in dialysis patients and have pleiotropic effects in addition to lowering total and low-density lipoprotein (LDL)-cholesterol. Because there is a paucity of data on the effect of statins on serum Prohepcidin levels in dialysis patients, this 8-week study was conducted to test the effect of fluvastatin (80 mg/day, n=22) compared with placebo (n=18) on circulating serum Prohepcidin, a prohormone of hepcidin, and high-sensitive C-reactive protein (hs-CRP) in dyslipidemic ESRD patients with renal anemia. Fluvastatin treatment decreased total cholesterol (P<0.05), LDL-cholesterol (P<0.01), hs-CRP (P<0.05) and serum Prohepcidin levels (P<0.05) significantly. Our pilot data suggest that short-term statin treatment may exert a beneficial effect on serum Prohepcidin levels in ESRD patients. The potential clinical benefits of statins on renal anemia need to be confirmed and expanded with an appropriately powered long-term study.
Robert Flisiak - One of the best experts on this subject based on the ideXlab platform.
-
Successful antiviral therapy is associated with a decrease of serum Prohepcidin in chronic hepatitis C.
World journal of gastroenterology, 2010Co-Authors: Jerzy Jaroszewicz, Magdalena Rogalska, Iwona Flisiak, Robert FlisiakAbstract:To assess serum concentrations of Prohepcidin in chronic hepatitis C individuals and evaluate their associations with disease activity and efficacy of pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. Prohepcidin was measured in sera of 53 chronic hepatitis C patients. Concentrations of Prohepcidin and other iron metabolism markers were analyzed at 9 time points before, during and after the end of antiviral therapy. In hepatitis C virus (HCV) genotype 1-infected individuals, a gradual decrease of Prohepcidin during antiviral therapy was observed in responders (88.8 +/- 14.7 ng/mL before therapy vs 60.6 +/- 0.3 ng/mL in the 48th wk, P = 0.04). In contrast, no decrease was observed in non-responders. A similar association was observed in HCV genotype 3a individuals, with a statistically significant decline in serum Prohepcidin only in the responder group (99.5 +/- 5.2 ng/mL at baseline vs 72.7 +/- 6.1 ng/mL in the 24th wk, P = 0.01). Moreover, HCV-RNA at week 12 of therapy was positively correlated with baseline (R = 0.63, P < 0.005) and week 12 (R = 0.60, P = 0.01) serum Prohepcidin concentrations in HCV genotype 1 infection. Successful PEG-IFN/RBV therapy results in a decline of serum Prohepcidin concentration in chronic hepatitis C, which may suggest a direct effect of HCV on iron metabolism at the prohormonal level of hepcidin.
-
618 SUCCESSFUL ANTIVIRAL THERAPY IS ASSOCIATED WITH THE DECREASE OF SERUM PROHEPCIDICIN IN CHRONIC HEPATITIS C
Journal of Hepatology, 2009Co-Authors: Jerzy Jaroszewicz, Magdalena Rogalska, Robert FlisiakAbstract:Abstract AIM: To assess serum concentrations of Prohepcidin in chronic hepatitis C individuals and evaluate their asso-ciations with disease activity and efficacy of pegylated interferon (PEG-IFN)/ribavirin (RBV) therapy. METHODS: Prohepcidin was measured in sera of 53 chronic hepatitis C patients. Concentrations of prohep-cidin and other iron metabolism markers were ana-lyzed at 9 time points before, during and after the end of antiviral therapy. RESULTS: In hepatitis C virus (HCV) genotype 1-in-fected individuals, a gradual decrease of Prohepcidin during antiviral therapy was observed in responders (88.8 ± 14.7 ng/mL before therapy vs 60.6 ± 0.3 ng/mL in the 48th wk, P = 0.04). In contrast, no decrease was observed in non-responders. A similar association was observed in HCV genotype 3a individuals, with a statisti-cally significant decline in serum Prohepcidin only in the responder group (99.5 ± 5.2 ng/mL at baseline vs 72.7 ± 6.1 ng/mL in the 24th wk, P = 0.01). Moreover, HCV-RNA at week 12 of therapy was positively correlated with baseline (R = 0.63, P < 0.005) and week 12 (R = 0.60, P = 0.01) serum Prohepcidin concentrations in HCV genotype 1 infection.
-
serum Prohepcidin reflects the degree of liver function impairment in liver cirrhosis
Biomarkers, 2008Co-Authors: Jerzy Jaroszewicz, Magdalena Rogalska, Robert FlisiakAbstract:AbstractIn the past few years the role of hepcidin metabolism disturbances, a recently described key regulator of iron metabolism, has been raised in patients with chronic liver diseases. The aim of this study was to assess the serum concentrations of Prohepcidin in liver cirrhosis of various aetiologies and their possible relationship with the disease activity. Prohepcidin was measured in the sera of 70 patients with liver cirrhosis of various aetiologies by an immunoassay technique. The serum concentrations of Prohepcidin were compared with the degree of liver insufficiency and biochemical markers of iron metabolism. A significant decrease in serum Prohepcidin was observed in patients with liver cirrhosis compared with healthy individuals (52.6±1.9 vs 79.5±9.7 ng ml−1, p<0.01); this was most prominent in patients with hepatitis C virus and alcohol-related liver cirrhosis. The association between serum Prohepcidin and the degree of liver dysfunction was observed in alcoholic liver cirrhosis, as illustrat...
-
Serum Prohepcidin reflects the degree of liver function impairment in liver cirrhosis.
Biomarkers : biochemical indicators of exposure response and susceptibility to chemicals, 2008Co-Authors: Jerzy Jaroszewicz, Magdalena Rogalska, Robert FlisiakAbstract:AbstractIn the past few years the role of hepcidin metabolism disturbances, a recently described key regulator of iron metabolism, has been raised in patients with chronic liver diseases. The aim of this study was to assess the serum concentrations of Prohepcidin in liver cirrhosis of various aetiologies and their possible relationship with the disease activity. Prohepcidin was measured in the sera of 70 patients with liver cirrhosis of various aetiologies by an immunoassay technique. The serum concentrations of Prohepcidin were compared with the degree of liver insufficiency and biochemical markers of iron metabolism. A significant decrease in serum Prohepcidin was observed in patients with liver cirrhosis compared with healthy individuals (52.6±1.9 vs 79.5±9.7 ng ml−1, p
